GLP-1 Medication Availability in 2026: Shortage Status, Supply Updates & What to Do
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 18, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
GLP-1 Availability in 2026: Current Status
As of early 2026, the acute shortage crisis that peaked in 2022–2024 has substantially resolved for most GLP-1 medications. Wegovy (semaglutide 2.4mg), Ozempic, Zepbound, and Mounjaro are generally available at most major US pharmacies, though spot shortages of specific doses and pen sizes still occur regionally. The FDA declared Wegovy and Ozempic no longer in shortage in 2024. Tirzepatide products (Zepbound, Mounjaro) have had more stable supply since launch.
Availability by Drug (March 2026)
Wegovy (semaglutide 2.4mg): Most doses available at major pharmacies. Spot shortages of the 1.7mg maintenance dose and 0.5mg starter dose reported in some regions. FDA shortage status: Resolved. Ozempic (semaglutide 0.5–2.0mg): Generally well-supplied. Higher doses (1.0mg, 2.0mg) occasionally limited. Diabetes patient advocacy groups report improved access vs. 2022–2023. Zepbound (tirzepatide 2.5–15mg): All doses generally available. Newer to market (2023); demand has not outpaced supply to the same degree as semaglutide. Mounjaro (tirzepatide 2.5–15mg): Good availability. Historically had fewer supply issues than semaglutide. Saxenda (liraglutide 3.0mg): Available but less demand since Wegovy/Zepbound entered market. Rybelsus (oral semaglutide): Generally available. Considered a lower-demand product.
What to Do If Your Dose Is Unavailable
Check multiple pharmacy chains: CVS, Walgreens, Rite Aid, Costco, Sam's Club, and independent pharmacies may have different stock levels for the same medication. Ask your pharmacist to check neighboring store locations or order from the warehouse. Use GoodRx or pharmacy comparison tools to check stock at different pharmacies in your area. Contact your prescriber: they may be able to prescribe an equivalent dose from a different pen configuration (e.g., multiple 0.5mg doses to reach a higher weekly dose), or temporarily dose-hold and restart when medication is available. Check the FDA drug shortage database (accessdata.fda.gov) for official shortage status. If supply is consistently unavailable in your area, ask your provider about switching to tirzepatide (Zepbound/Mounjaro), which has had more stable supply.
How the Shortage Created the Compounding Market
The 2022–2024 semaglutide shortage was the direct driver of the compounded semaglutide market. Under FDA regulations, when a branded drug is officially listed as in shortage, compounding pharmacies can legally produce compounded versions to fill the gap. This created a large market for compounded semaglutide through telehealth platforms. When the FDA removed semaglutide from its shortage list in 2024–2025, it technically removed the primary legal basis for broad compounding, though enforcement has been inconsistent and many pharmacies continue to operate. For compounded tirzepatide: the FDA has taken a stricter stance since tirzepatide was never on the shortage list, making compounded tirzepatide legally more problematic than compounded semaglutide.
Strategies for Maintaining Uninterrupted Access
Refill early: most insurance plans allow refills when you have 7–10 days remaining. Don't wait until you're completely out, especially for medications that require titration. Use a 90-day supply: 90-day fills from mail-order pharmacies often have better stock than retail pharmacies and reduce the frequency of potential access disruptions. Build a prescriber relationship: providers who know your case can advocate with prior authorization, provide samples, or adjust treatment if supply issues arise. Sign up for pharmacy notifications: many chains allow you to be notified when a specific medication is in stock. Consider pharmacy transfer: if your usual pharmacy consistently has stock issues, transferring to a pharmacy with better supply chain access may help.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Continue Your GLP-1 Research
Doctor Prescribed Semaglutide Cost Without Insurance: Complete 2026 Guide
Access & Cost · 9 min read
Compounded Semaglutide Safety: What You Need to Know Before Using It
Safety & Access · 10 min read
GLP-1 Medications: Complete 2026 Comparison Guide (Wegovy, Ozempic, Zepbound, Mounjaro)
Drug Comparison · 15 min read
